Somatic Test
prev next

TARGT First

Biomarker testing for All at an affordable price
TARGT First is one of the most focused and affordable pan-solid Cancer Gene panels available, with 72 most commonly mutated cancer-associated genes with a high level of evidence for both targeted therapy and prognostication. line
This test covers the most known genomic biomarkers for which NCCN and FDA-approved therapy options are available to treat solid cancers. It is developed to make cancer biomarker testing affordable and accessible for every cancer patient. line
Additionally, TARGT First can provide a combined NGS approach using solid & liquid biopsy to gain insights from both the sample sources, thereby mitigating each other’s limitations and aiding in the optimal resolution of the disease genomic landscape. line

SNVs/InDels & CNAs Coverage in TARGT First

ABL1 ALK APC AR ATM BARD1 BMPR1A BRAF BRCA1 BRCA2
BRIP1 CDK12 CDK4 CDK6 CDKN2A CHEK1 CHEK2 CTNNB1 EGFR EPCAM
ERBB2 ERBB3 EZH2 FANCL FGFR1 FGFR2 FGFR3 GAPDH IDH1 IDH2
JAK2 KIT KRAS MAP2K1 MAP2K2 MDM2 MET
(exon 14 skipping)		 MLH1 MLH3 MSH2
MSH6 MUTYH NRAS PALB2 PDGFRA PDGFRB PIK3CA PMS1 PMS2 POLD1
POLE POLH PTEN RAD50 RAD51 RAD51B RAD51C RAD51D RAD54L RB1
RET ROS1 SMAD4 STK11 TP53 TSC1 TSC2
Gene Fusions Coverage in TARGT First

ALK FGFR2 FGFR3 MET
(exon 14 skipping)		 NRG1 NRG2 NTRK1 NTRK2 NTRK3 RET
ROS1

download
Downloads
book
Book your Test
ct
Compare Our Tests
loader